Comparison between sitagliptin as add‐on therapy to insulin and insulin dose‐increase therapy in uncontrolled Korean type 2 diabetes: CSI study
- 24 March 2012
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 14 (9), 795-802
- https://doi.org/10.1111/j.1463-1326.2012.01600.x
Abstract
Aim: Individuals requiring insulin therapy for type 2 diabetes often require escalation of their regimen to achieve glycaemic control. Optimal management strategies for uncontrolled type 2 diabetes would improve glycaemic control without hypoglycaemia and weight gain. This study compared the efficacy and tolerability of adding sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, and an up to 20% increase in insulin dose in patients with uncontrolled type 2 diabetes on insulin therapy. Methods: We conducted a 24‐week, randomized, active‐competitor, parallel‐group study in subjects with uncontrolled type 2 diabetes [haemoglobin A1c (HbA1c) = 7.5–11%] currently using insulin therapy. Subjects were randomly assigned to either the sitagliptin adding (100 mg daily, n = 70) or an insulin‐increasing arm (≥10% at week 12 and ≥10% at week 24, n = 70) while continuing other medications. Results: Average baseline HbA1c was 9.2% in both groups. HbA1c decreased more at 24 weeks in the sitagliptin adding than the insulin‐increasing arm (−0.6 ± 0.1% vs. −0.2 ± 0.1%, p < 0.01). Insulin was increased by 25% at 24 weeks in the insulin‐increasing group. Hypoglycaemic events were less common and less severe in sitagliptin adding arm than insulin‐increasing arm (7.0 vs. 14.3 events per patient‐year, p < 0.05). Weight was stable in the sitagliptin adding subjects (68.6 ± 11.6 vs. 68.1 ± 11.4 kg) but increased in the insulin‐increasing subjects (66.2 ± 10.6 vs. 67.4 ± 9.7 kg, p < 0.05). Other adverse events occurred at similar rates in both arms. Conclusions: Compared to a 25% increase in insulin dose, adding sitagliptin to an insulin‐based regimen was more effective at lowering HbA1c and associated with less hypoglycaemia and weight gain over 24 weeks. Clinical trial number: NCT01100125.This publication has 47 references indexed in Scilit:
- Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trialDiabetologia, 2011
- Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 DiabetesDiabetes Care, 2011
- Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trialDiabetes, Obesity and Metabolism, 2011
- Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes MellitusDiabetes & Metabolism Journal, 2011
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes, Obesity and Metabolism, 2007
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trialDiabetes, Obesity and Metabolism, 2007
- A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia, 2006
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006
- When oral agents fail: practical barriers to starting insulinInternational Journal of Obesity, 2002